MX2018008008A - Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. - Google Patents

Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.

Info

Publication number
MX2018008008A
MX2018008008A MX2018008008A MX2018008008A MX2018008008A MX 2018008008 A MX2018008008 A MX 2018008008A MX 2018008008 A MX2018008008 A MX 2018008008A MX 2018008008 A MX2018008008 A MX 2018008008A MX 2018008008 A MX2018008008 A MX 2018008008A
Authority
MX
Mexico
Prior art keywords
treatment
ovarian cancer
antibody
combination
hdac inhibitor
Prior art date
Application number
MX2018008008A
Other languages
English (en)
Inventor
Ordentlich Peter
Meyers Michel
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2018008008A publication Critical patent/MX2018008008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para el tratamiento de cáncer de ovario recurrente pre-tratado fuertemente; en particular se proporcionan métodos para el tratamiento de cáncer de ovario recurrente pre-tratado fuertemente con una combinación de entinostat y un anticuerpo anti-PD-L1.
MX2018008008A 2015-12-28 2016-12-28 Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico. MX2018008008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562271914P 2015-12-28 2015-12-28
PCT/US2016/068836 WO2017117196A1 (en) 2015-12-28 2016-12-28 Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
MX2018008008A true MX2018008008A (es) 2018-11-09

Family

ID=59225631

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008008A MX2018008008A (es) 2015-12-28 2016-12-28 Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.

Country Status (12)

Country Link
US (1) US20190290759A1 (es)
EP (1) EP3397262A4 (es)
JP (1) JP2018538321A (es)
KR (1) KR20180095586A (es)
CN (1) CN108430472A (es)
AU (1) AU2016382780A1 (es)
BR (1) BR112018013094A2 (es)
CA (1) CA3004369A1 (es)
IL (1) IL259416A (es)
MX (1) MX2018008008A (es)
RU (1) RU2018127640A (es)
WO (1) WO2017117196A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120204A2 (en) * 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2019079548A1 (en) 2017-10-18 2019-04-25 Forty Seven, Inc. OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT
SI3697819T1 (sl) * 2017-10-18 2023-01-31 Forty Seven, Inc. Zdravljenje raka jajčnikov z anti-CD47 in anti-PD-L1
BR112022020285A2 (pt) * 2020-04-07 2022-12-06 Metanoi Therapeutics Inc Formulação de etanolamina para tratar carcinoma epitelial de ovário
US11944615B2 (en) * 2020-09-03 2024-04-02 New York University Combination therapy for treatment of LKB1 deficient cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966998B2 (en) * 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015120382A1 (en) * 2014-02-07 2015-08-13 The Johns Hopkins University Predicting response to epigenetic drug therapy
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
US20170209574A1 (en) * 2014-10-03 2017-07-27 Novartis Ag Combination therapies
JP2018519335A (ja) * 2015-06-29 2018-07-19 シンダックス ファーマシューティカルズ， インコーポレイテッド がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ

Also Published As

Publication number Publication date
BR112018013094A2 (pt) 2018-12-11
EP3397262A4 (en) 2019-06-19
WO2017117196A1 (en) 2017-07-06
AU2016382780A1 (en) 2018-05-17
KR20180095586A (ko) 2018-08-27
RU2018127640A (ru) 2020-01-30
US20190290759A1 (en) 2019-09-26
CA3004369A1 (en) 2017-07-06
JP2018538321A (ja) 2018-12-27
EP3397262A1 (en) 2018-11-07
CN108430472A (zh) 2018-08-21
IL259416A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EP3733704A4 (en) Anti-pd-l1 antibody and uses thereof
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12019500552A1 (en) Antibody specifically binding to pd-1 and functional fragment thereof
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
EP3550048A4 (en) STEEL FOR SOFT NITRATION AND COMPONENT
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2019006005A (es) Metodos para la deteccion de cancer.
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2015010789A (es) Anticuerpos anti-pcsm.
AU201710710S (en) bottle